早期麻疹疫苗接种对长期保护效果的系统综述
该系统综述与荟萃分析评估了12月龄前接种首剂含麻疹疫苗(MCV1)与12月龄及以上接种相比,对长期免疫原性和疫苗效果的影响,长期定义为接种后至少一年。共纳入51篇文献。结果显示,12月龄前接种者总体麻疹风险更高(RR=3.16,95%CI:2.00-5.01),但血清转化和血清阳性率不受首剂接种年龄影响,而抗体水平显著较低(MD=-0.40,95%CI:-0.71至-0.09)。
要点
- 12月龄前接种MCV1者长期麻疹风险是12月龄及以上接种者的3.16倍(RR=3.16,95%CI:2.00-5.01)。
- 首剂接种年龄越大,麻疹风险越低,≥15月龄接种者风险低于12-14月龄或<12月龄者。
- 血清转化和血清阳性率不受首剂接种年龄影响,但<12月龄接种者抗体水平显著较低(MD=-0.40,95%CI:-0.71至-0.09)。
核心结论
- 长期麻疹血清转化和血清阳性率似乎不受MCV1接种年龄影响,但疫苗效果随接种年龄减小而降低。
- 证据不足以评估MCV1接种年龄对免疫钝化的影响。
研究设计与样本
- 纳入51篇文献,其中23篇报告疫苗效果相关结局,30篇报告免疫原性相关结局。
- 纳入标准为包含<12月龄接种婴儿队列并评估长期免疫原性、疫苗效力或效果的研究。
主要发现
- <12月龄接种MCV1的婴儿与≥12月龄接种者相比,总体麻疹风险更高(RR=3.16,95%CI:2.00-5.01;OR=2.46,95%CI:1.40-4.32)。
- 麻疹风险随首剂接种年龄增加而降低,≥15月龄接种一剂者风险低于12-14月龄或<12月龄接种者。
- 麻疹血清转化和血清阳性率不受首剂接种年龄影响,但<12月龄接种组抗体水平显著较低(MD=-0.40,95%CI:-0.71至-0.09)。
关键数值与推荐
- 长期定义为接种后至少一年。
- <12月龄接种MCV1者与≥12月龄接种者比较,麻疹风险RR=3.16(95%CI:2.00-5.01),OR=2.46(95%CI:1.40-4.32)。
- <12月龄接种组抗体水平平均差MD=-0.40(95%CI:-0.71至-0.09)。
临床怎么用
- 对于<12月龄婴儿,若需提前接种MCV1(如前往高流行区),应知晓其长期疫苗效果可能降低。
- 应按照免疫规划在≥12月龄常规接种MCV1,并确保后续剂次完成。
- 对早期接种MCV1的儿童,可考虑依据指南评估是否需要补充接种以增强长期保护。
局限性
- 证据不足以评估MCV1接种年龄对免疫钝化的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In North America, the first dose of a measles-containing vaccine (MCV1) is administered at ≥12 months of age. However, MCV1 may be given to infants <12 months living in highly endemic areas or traveling to these areas. Although an early dose of MCV1 leads to immediate protection, it remains unclear how this impacts long-term immunity. METHODS: This systematic review and meta-analysis evaluates the impact of MCV1 given at <12 months vs. ≥12 months of age on long-term immunogenicity and vaccine effectiveness, with long-term defined as at least one-year post-vaccination. PubMed, EMBASE, Global Health, Web of Science and Scopus were searched on October 31st, 2019. Studies were included if they included a cohort of infants vaccinated <12 months of age and evaluated long-term immunogenicity, vaccine efficacy, or effectiveness. RESULTS: A total of 51 texts were identified: 23 reported outcomes related to vaccine effectiveness and 30 to immunogenicity. Infants vaccinated with MCV1 < 12 months of age showed an overall higher risk of measles compared to ≥12 months of age (RR = 3.16, 95% CI: 2.00, 5.01; OR = 2.46, 95% CI: 1.40, 4.32). Risk of measles decreased with increasing age at first vaccination, with those vaccinated with one dose ≥15 months at a lesser risk compared to 12-14 months or <12 months. Measles seroconversion and seropositivity was not affected by age at first vaccination, but antibody levels were significantly lower in the MCV1 < 12-month group (MD = -0.40, 95% CI: -0.71, -0.09). CONCLUSION: Long-term measles seroconversion and seropositivity did not appear to be affected by age at MCV1, while vaccine effectiveness decreased with younger age. There was not enough evidence to look at the effect of age at MCV1 on immune blunting.
引用
- Xu J, Doyon-Plourde P, Tunis M, et al. Effect of early measles vaccination on long-term protection: A systematic review. Vaccine. 2021. PMID: 33926750. doi:10.1016/j.vaccine.2021.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。